Cytomegalovirus infection as a cause of cytopenia after chemotherapy for hematological malignancies

Indian Pediatrics

Volumn 50, Issue 2, 2013, Pages 197-201

  Kanvinde, Shailesh ^a   Bhargava, Pallavi ^a   Patwardhan, Sampada ^a  

^a DEENANATH MANGESHKAR HOSPITAL   (India)

Author keywords

Chemotherapy; Cytomegalovirus; Cytopenia; Leukemia

Indexed keywords

ASPARAGINASE; CIDOFOVIR; CYTARABINE; CYTOMEGALOVIRUS ANTIGEN PP65; DAUNORUBICIN; GANCICLOVIR; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN DETECTION; CANCER CHEMOTHERAPY; CHILD; CHORIORETINITIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DIARRHEA; DISEASE ASSOCIATION; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; MAINTENANCE THERAPY; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VIRUS IDENTIFICATION;

ANTINEOPLASTIC AGENTS; CHILD; CYTOMEGALOVIRUS INFECTIONS; HUMANS; LEUKOPENIA; LYMPHOMA, NON-HODGKIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES;

EID: 84877073875     PISSN: 00196061     EISSN: 09747559     Source Type: Journal    
DOI: 10.1007/s13312-013-0066-4     Document Type: Conference Paper

References (22)

1. Ljungman P, Reusser P, de la Camara R, Einsele H, Engelhard D, Ribaudi P, et al. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant. 2004;33:1075-1081.
2. Zaia J. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:633-638.
3. Fraser G, Walker I, and the Canadian Blood and Marrow Transplant Group. Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: A description of current practices and comparison with Centers for Disease Control / Infectious Diseases Society of America / American Society for Blood and Marrow Transplantation guideline recommendations. Biol Blood Marrow Transplant. 2004;10:287-297.
4. Montesinos P, Sanz J, Cantero S, Lorenzo I, Martin G, Saavedra S, et al. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2009;15:730-740.
5. Dominietto A, Raiola A, van Lint M, Lamparelli T, Gualandi F, Berisso G, et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol. 2001;112:219-227.
6. Castagnola E, Cristina E, Dufour C. High-dose oral gancyclovir for management of CMV-symptomatic infection in a child with acute lymphoblastic leukemia. Med Pediatr Oncol. 2002;38:295-296.
7. Armstrong D, Haghbin M, Balakrishnan S, Murphy M. Asymptomatic cytomegalovirus infection in children with leukemia. Am J Dis Child. 1971;122:404-407.
8. Nguyen Q, Estey E, Raad I, Rolston K, Kantarjian H, Jacobson K, et al. Cytomegalovirus pneumonia in adults with leukemia: An emerging problem. Clin Infect Dis. 2001;32:539-545.
9. Chemaly R, Torres H, Hachem R, Nogueras G, Aguilera E, Younes A, et al. Cytomegalovirus pneumonia in patients with lymphoma. Cancer. 2005;104:1213-1220.
10. Advani S, Pai S, Adde M, Vaidya S, Vats S, Naresh K, et al. Preliminary report of an intensified, short duration chemotherapy protocol for the treatment of pediatric non-Hodgkin's lymphoma in India. Ann Oncol. 1997;8:893-897.
11. Crippa F, Corey L, Chuang EL, Sale G, Boeckh M. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis. 2001;32:214-219.
12. Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood. 1992;80:1358-1364.
13. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86:2815-2820.
14. Avery RK, Adal KA, Longworth DL, Bolwell BJ. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy. Bone Marrow Transplant. 2000;26:763-767.
15. Meyers JD, Ljungman P, Fisher LD. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis. 1990;162:373-380.
16. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063-4071.
17. Boeckh M, Ljungman P. How I treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113:5711-5719.
18. Venkitaraman A, Seigneurin J, Lenoir G, Jacob John T. Infections due to the Human Herpesviruses in Southern India: A Seroepidemiological Survey. Int J Epidemiol. 1986;15:561-566.
19. Sing G, Ruscetti F. Preferential suppression of myelopoiesis in normal human bone marrow cells after in vitro challenge with human cytomegalovirus. Blood. 1990;75:1965-1973.
20. Simmons P, Kaushansky K, Torok-Storb B. Mechanisms of cytomegalovirus-mediated myelosuppression: Perturbation of stromal cell function versus direct infection of myeloid cells. Proc Natl Acad Sci USA. 1990;87:1386-1390.
21. Nichols W, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185:273-282.
22. Humar A, Wood S, Lipton J, Messner H, Meharchand J, McGeer A, et al. Effect of cytomegalovirus infection on 1-year mortality rates among recipients of allogeneic bone marrow transplants. Clin Infect Dis. 1998;26:606-610.